Episodes

  • Beyond Fentanyl: The Rise of Synthetic Opioids Ten Times More Potent

    Beyond Fentanyl: The Rise of Synthetic Opioids Ten Times More Potent
    Oct 15 2026
    A new class of synthetic opioids known as orphine analogues has been detected in illicit drug supplies across 22 American states, raising concerns about the next evolution of the opioid crisis. Some of these compounds have demonstrated pharmacological potency substantially greater than fentanyl, while conventional drug screening methods may fail to identify them. We examine how these substances affect the brain, why respiratory depression is so dangerous, and what makes their detection and treatment particularly challenging. We also explore the implications for emergency medicine, forensic toxicology, and the future of opioid pharmacology.
    Show More Show Less
    3 mins
  • Why Antidepressants Sometimes Stop Working: The Science Behind the Loss of Response

    Why Antidepressants Sometimes Stop Working: The Science Behind the Loss of Response
    Oct 11 2026
    Antidepressants influence neurotransmission relatively quickly, yet meaningful clinical improvement often takes longer. This episode explores receptor signaling, neural adaptation, stress circuitry, and neuroplasticity in depression treatment. Discover why changes in brain function are more complicated than the familiar chemical-imbalance explanation.
    Show More Show Less
    4 mins
  • When Antipsychotics Aren’t the Answer: The Medical Illness That Can Look Like Psychosis

    When Antipsychotics Aren’t the Answer: The Medical Illness That Can Look Like Psychosis
    Oct 7 2026
    Hallucinations, paranoia, agitation, and bizarre behavior can reasonably lead clinicians toward antipsychotic treatment, but what happens when the underlying illness isn’t primarily psychiatric? Anti-NMDA receptor encephalitis can initially resemble a severe psychiatric disorder before neurological symptoms emerge. This episode examines the diagnostic clues that can change the entire treatment strategy.
    Show More Show Less
    3 mins
  • Why Do SSRIs Take Weeks to Work If They Change Serotonin Within Hours?

    Why Do SSRIs Take Weeks to Work If They Change Serotonin Within Hours?
    Oct 4 2026
    SSRIs begin altering serotonin signaling within hours, yet people with depression or anxiety are often told that meaningful improvement may take weeks. Why does the brain respond so slowly if the medication begins working almost immediately? The answer reveals why the familiar idea of antidepressants simply “correcting a chemical imbalance” is far too simplistic. This episode explores serotonin transporters, receptor adaptation, neural plasticity, and the gradual biological changes that may contribute to antidepressant effects. It also explains why an SSRI can be pharmacologically active long before a person notices a meaningful psychological difference.
    Show More Show Less
    4 mins
  • Beyond the Daily Pill: The Injection Shaking Up Bipolar Treatment

    Beyond the Daily Pill: The Injection Shaking Up Bipolar Treatment
    Sep 13 2026
    A new study published in The American Journal of Psychiatry analyzed electronic health records from 2,086 individuals with bipolar disorder in Hong Kong treated between 2004 and 2023. While long-acting injectable antipsychotics (LAIAs) are already widely recognized for treating schizophrenia, robust comparative guidance for bipolar disorder has historically been limited. The researchers found that patients receiving LAIAs had a significantly lower risk of psychiatric hospitalization compared to those on traditional oral antipsychotics. In addition, the injectable treatments were tied to a reduced recurrence rate of manic and mixed episodes, offering compelling evidence for their expanded clinical role.
    Show More Show Less
    3 mins
  • A Simpler Way to Ease OCD When Bipolar Is Also in the Picture

    A Simpler Way to Ease OCD When Bipolar Is Also in the Picture
    Sep 10 2026
    Many people live with both bipolar disorder and obsessive-compulsive symptoms. The usual medicines for OCD can make bipolar moods swing more wildly. A new study points to a different option that may help without that risk.
    Show More Show Less
    2 mins
  • The FDA Is Fast-Tracking Psychedelics. Noribogaine Is the Test Case That Is Not a Trip.

    The FDA Is Fast-Tracking Psychedelics. Noribogaine Is the Test Case That Is Not a Trip.
    Sep 7 2026
    After an executive order pushing HHS to speed mental-health treatments, the FDA issued priority vouchers for psilocybin in depression and methylone in PTSD and cleared the first U.S. trial of an ibogaine-related drug. That compound is noribogaine, aimed at alcohol use disorder, and its developers argue it is not hallucinogenic. The scientific question is no longer whether Washington is interested. It is whether cardiac risk, blinding, and psychotherapy can survive a real review.
    Show More Show Less
    3 mins
  • Know Your Brain: The Four Lobes and What They Actually Do

    Know Your Brain: The Four Lobes and What They Actually Do
    Aug 30 2026
    This episode breaks down the brain's four primary lobes — frontal, parietal, temporal, and occipital — and explains, in plain terms, what each one actually does and what happens when it's damaged or atypical. Along the way, the conversation touches on how differences in these brain regions show up in conditions like ADHD and autism spectrum disorder. It's a clear, foundational look at neuroanatomy for anyone curious about the biological side of how we think, feel, and behave.
    Show More Show Less
    17 mins